Valsartan Tablet 160 mg (Valsartan)
Valsartan
Prescription medication
Hallym Pharmaceutical Co., Ltd.
MFDS item code 201105415 · Notified 2011.08.18
This product's status changed to Approval withdrawn on 2023.07.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication helps control blood pressure in patients with essential hypertension and can be safely used in heart failure patients who are intolerant to ACE inhibitors. It also shows a reduction in mortality risk in patients with left ventricular dysfunction after myocardial infarction. This drug improves blood pressure and symptoms of heart failure and contributes to the prevention of complications following myocardial infarction. Thus, it is used for essential hypertension, heart failure (including patients intolerant to ACE inhibitors), and reduction of mortality risk post-myocardial infarction.
* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time every day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended oral dose is 80 mg of valsartan once daily. The blood-pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If further blood-pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily. Over the following several weeks, the dose may be increased, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension 6) Children: The safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: The safety and efficacy have not been established in children and adolescents under 18 years of age.
This drug can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters. Therefore, it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant, may become pregnant, or are breastfeeding should not take this medication. Patients with severe liver or kidney dysfunction, hereditary angioedema, primary hyperaldosteronism, and certain other conditions should not use this drug. Elderly patients, those with hyperkalemia, liver impairment, and patients with heart failure should be monitored carefully while taking this medication, especially since blood pressure can drop rapidly; starting with a low dose and increasing gradually is safer. As this drug has blood pressure-lowering effects, dizziness or fainting may occur when first taking it, so caution is advised, especially with driving or operating machinery. Potassium levels in the blood may elevate while taking this drug; therefore, careful management is required when using potassium-sparing diuretics or potassium supplements. Combination with other antihypertensives, diuretics, or non-steroidal anti-inflammatory drugs (NSAIDs) can lead to changes in effects due to drug interactions, so consultation with a healthcare professional is necessary. Patients with heart failure or post-myocardial infarction should take this medication while regularly monitoring kidney function and electrolyte status; combination with ACE inhibitors or aliskiren is not recommended. Safety in children and adolescents has not been established, and it is advisable not to use this drug. In cases of overdose, symptoms such as hypotension, altered consciousness, and shock may occur, requiring immediate medical attention. This medication should be kept out of the reach of children, and it is recommended not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture; therefore, it should be stored in a tightly closed container. Additionally, it is crucial to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Orange oval film-coated tablets
98 tablets (14 tablets/PTP packaging x 7), 30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan
Prescription medication
Hallym Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.